6 results about "Benzodiazepine" patented technology

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

This invention discloses an AI-designed benzodiazepine derivative, a pharmaceutical composition, and its uses. The benzodiazepine derivative has the structure of Formula I: wherein R1 is any one of H, deuterium, halogen, or C1-C3 alkoxy group; A is a nitrogen-containing heterocyclic group; n is 0 or 1; and R2 and R3 are hydrogen, C1-C6 alkyl group, or C4-C6 alkyl group. 20 Any of the polycyclic cycloalkyl groups; or, R2 and R3 can form a C4-C4 group together with the N they are attached to. 20 The polycyclic heterocyclic group structure. The benzodiazepine derivative of this invention, as the active ingredient in drugs for preventing and / or inhibiting myopia progression, can significantly improve selectivity for M2 receptors and significantly reduce inhibitory effects on M3 receptors, with an M3 / M2 IC50 ratio. 50 The ratio increases significantly, enabling effective treatment of myopia without affecting pupil size, and helps improve the targeted nature of treatment and patient comfort.

The present invention relates to the field of pharmaceutical biology, and particularly relates to a heterocyclic compound, a method for preparing same, and use thereof. More particularly, the present invention relates to a pyrrolo-benzodiazepine compound, a drug linker thereof, a drug conjugate thereof, or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, a nitrogen oxide, an isotopically labeled form, a metabolite or prodrug, or a pharmaceutical composition thereof, a method for preparing same, and use thereof as a medicament for treating diseases associated with abnormal cell proliferation.

Provided in the present invention is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating (patients with) insomnia comorbid with different diseases.